NFKB2 gene expression in patients with peptic ulcer diseases and gastric cancer.


Journal

Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 19 11 2019
accepted: 31 01 2020
pubmed: 15 2 2020
medline: 21 10 2020
entrez: 15 2 2020
Statut: ppublish

Résumé

Gastric cancer is one of the most common worldwide types of cancer. It is a multifactorial disease and both environmental and genetic factors play an important role in its etiology. Evaluation of the relative expression level of NFKB2 gene in two groups of patients: peptic ulcer and gastric cancer and its role in the pathomechanism of these diseases was the aim of this study. RNA was isolated from: 79 samples of peptic ulcer, 22 gastric cancer and 11 control tissue. The real-time PCR technique was used to study the expression of NFKB2 gene. The relative expression level of NFKB2 gene was a variable in all three studied groups. The relative NFKB2 gene expression depends on the type of a disease. Peptic ulcer cases showed the increased relative NFKB2 gene expression to control group (p = 0.0000). Cancer cases presented decreased relative NFKB2 gene expression to normal stomach tissue (p = 0.0183). There are statistically important differences in the investigated gene expression between peptic ulcer, where the expression level is higher comparing to gastric cancer and control tissue which confirmed that such an activation is connected with an inflammatory process. The relative expression level of NFKB2 is decreased in cancer cases as opposed to control tissue and peptic ulcer cases which could suggest that during carcinogenesis of gastric cancer inhibition of NF-kB pathway takes place which could be a promising factor for patients.

Identifiants

pubmed: 32056043
doi: 10.1007/s11033-020-05299-5
pii: 10.1007/s11033-020-05299-5
doi:

Substances chimiques

NF-kappa B p52 Subunit 0
NFKB2 protein, human 0
RNA, Messenger 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2015-2021

Subventions

Organisme : Department of Pharmaceutical Biochemistry and Molecular Diagnostics
ID : 503/3-015-02/503-31-001
Organisme : Research task of the Medical University of Lodz
ID : 502-03/3-015-02/502-34-080
Organisme : Research task of the Medical University of Lodz
ID : 502-03/3-015-02/502-34-089

Références

Karimi P, Islami F, Anandasabapathy Sh, Freedmanand ND, Kamangar F (2014) Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev 23:700–713. https://doi.org/10.1158/1055-9965.EPI-13-1057
doi: 10.1158/1055-9965.EPI-13-1057 pubmed: 24618998 pmcid: 4019373
Cavaleiro-Pinto M, Peleteiro B, Lunet N, Barros H (2011) Helicobacter pylori infection and gastric cardiacancer: systematic review and meta-analysis. Cancer Causes Control 22:375–387. doi: https://doi.org/10.1007/s10552-010-9707-2
doi: 10.1007/s10552-010-9707-2 pubmed: 21184266
Kopan R, Ilagan MX (2009) The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137(2):216–233. doi: https://doi.org/10.1016/j.cell.2009.03.045
doi: 10.1016/j.cell.2009.03.045 pubmed: 19379690 pmcid: 19379690
Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, Zhao S, Xiong Y, Guan KL (2008) TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol 28:2426–2436. doi: https://doi.org/10.1128/MCB.01874-07
doi: 10.1128/MCB.01874-07 pubmed: 18227151 pmcid: 2268418
Hoesel B 1, Schmid JA (2013) The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer 12:86. doi: https://doi.org/10.1186/1476-4598-12-86
doi: 10.1186/1476-4598-12-86 pubmed: 23915189 pmcid: 3750319
Guo X, Koff JL, Moffitt AB, Cinar M, Ramachandiran S, Chen Z, Switchenko JM, Mosunjac MI, Neill SG, Mann KP et al (2017) Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype. Oncogene 20(29):4224–4232. doi: https://doi.org/10.1038/onc.2017.90 36 ) .
doi: 10.1038/onc.2017.90
Oeckinghaus A, Sankar G (2009) The NF-κB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 1(4):a000034. https://doi.org/10.1101/cshperspect.a000034
doi: 10.1101/cshperspect.a000034 pubmed: 20066092 pmcid: 20066092
Israël A (2010) The IKK complex, a central regulator of NF-κB activation. Cold Spring Harb Perspect Biol 2:a000158. https://doi.org/10.1101/cshperspect.a000158
doi: 10.1101/cshperspect.a000158 pubmed: 20300203 pmcid: 2829958
Vallabhapurapu S, Karin M (2009) Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 27:693–733. doi: https://doi.org/10.1146/annurev.immunol.021908.132641
doi: 10.1146/annurev.immunol.021908.132641 pubmed: 19302050
Spehlmann ME, Eckmann L (2009) Nuclear factor-kappa B in intestinal protection and destruction. Curr Opin Gastroenterol 25:92–99. doi: https://doi.org/10.1097/MOG.0b013e328324f857
doi: 10.1097/MOG.0b013e328324f857 pubmed: 19528876
Kang MJ, Ryu BK, Lee MG, Han J, Lee JH, Ha TK, Byun DS, Chae KS, Lee BH, Chun HS et al (2008) NF-κB activates transcription of the RNA-binding factor HuR, via PI3K-AKT signalling, to promote gastric tumorigenesis. Gastroenterology 135(6):2030–2042. doi: https://doi.org/10.1053/j.gastro.2008.08.009
doi: 10.1053/j.gastro.2008.08.009 pubmed: 18824170
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-∆∆Cq method. Methods 25:402–408. doi: https://doi.org/10.1006/meth.2001.1262
doi: 10.1006/meth.2001.1262 pubmed: 11846609
Xia Y, Shen S, Verma IM (2014) NF-κB, an active player in human cancers. Cancer Immunol Res 2:823–830. doi: https://doi.org/10.1158/2326-6066.CIR-14-0112
doi: 10.1158/2326-6066.CIR-14-0112 pubmed: 25187272 pmcid: 4155602
Knittel1 G, Liedgens P, Korovkina D, Pallasch CP, Reinhardt HC (2016) Rewired NFkB signalling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma. Eur J Haematol 97:499–510. doi: https://doi.org/10.1111/ejh.12792
doi: 10.1111/ejh.12792 pubmed: 27526684
Shaffer AL, Young RM, Staudt LM (2012) Pathogenesis of human B cell lymphomas. Annu Rev Immunol 30:565–610. doi: https://doi.org/10.1146/annurev-immunol-020711-075027
doi: 10.1146/annurev-immunol-020711-075027 pubmed: 22224767
Ni H, Ergin M, Huang Q, Qin JZ, Amin HM, Martinez RL, Saeed S, Barton K, Alkan S et al (2001) Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF‐kappa B induces apoptosis. Br J Haematol 115:279–286. doi: https://doi.org/10.1046/j.1365-2141.2001.03102.x
doi: 10.1046/j.1365-2141.2001.03102.x pubmed: 11703322
Baldwin AS (2001) Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 107:241–246. doi: https://doi.org/10.1172/JCI11991
doi: 10.1172/JCI11991 pubmed: 11160144 pmcid: 199203
Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, Sonenshein GE (1997) Aberrant NF-κB/Rel expression and pathogenesis of breast cancer. J Clin Invest 100:2952–2960. doi: https://doi.org/10.1172/JCI119848
doi: 10.1172/JCI119848 pubmed: 9399940 pmcid: 508506
Duffey D, Chen Z, Dong G, Ondrey FG, Wolf JS, Brown K, Siebenlist U, Van Waes C (1999) Expression of a dominant negative mutant inhibitor of NF-κB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression and tumour growth in vivo. Cancer Res 59:3468–3474
pubmed: 10416612
Basseres DS, Ebbs A, Levantini E, Baldwin AS (2010) Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis. Cancer Res 70:3537–3546. doi: https://doi.org/10.1158/0008-5472.CAN-09-4290
doi: 10.1158/0008-5472.CAN-09-4290 pubmed: 20406971 pmcid: 2862109
Razani B, Reichardt AD, Cheng G (2011) Non-canonical NF‐kappaB signaling activation and regulation: principles and perspectives. Immunol Rev 244:44–54. doi: https://doi.org/10.1111/j.1600-065X.2011.01059.x
doi: 10.1111/j.1600-065X.2011.01059.x pubmed: 22017430
Fullard N, Wilson CL, Oakley F (2012) Roles of c-Rel signalling in inflammation and disease. Int J of Biochem Cell Biol 44:851–860. doi: https://doi.org/10.1016/j.biocel.2012.02.017
doi: 10.1016/j.biocel.2012.02.017
Lawrence T (2009) The nuclear factor NF-κB pathway in inflammation. Cold Spring Harb Perspect Biol 1(6):a001651. https://doi.org/10.1101/cshperspect.a001651
doi: 10.1101/cshperspect.a001651 pubmed: 2882124 pmcid: 2882124
Yang X, Sun R, Ci L, Wang N, Yang S, Shi J, Yang H, Zhang M, Fei J (2018) Tracing the dynamic expression of the Nfκb2 gene during inflammatory processes by in vivo bioluminescence imaging in transgenic mice. Biochem Biophys Res Commun 18:41–47. doi: https://doi.org/10.1016/j.bbrc.2018.04.126
doi: 10.1016/j.bbrc.2018.04.126
Grondona P, Bucher P, Schulze-Osthoff K, Hailfinger S, Schmitt A (2018) NF-κB activation in lymphoid malignancies: genetics, signaling, and targeted therapy. Biomedicines 26(6:2):E38. https://doi.org/10.3390/biomedicines6020038
doi: 10.3390/biomedicines6020038
Porta C, Rimoldi M, Raes G, Brys L, Ghezzi P, Di Liberto D, Dieli F, Ghisletti S, Natoli G, De Baetselier P et al (2009) Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. Proc Natl Acad Sci USA 106:14978–14983. https://doi.org/10.1073/pnas.0809784106
doi: 10.1073/pnas.0809784106 pubmed: 19706447

Auteurs

Żebrowska-Nawrocka Marta (ŻN)

Laboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Medical University of Lodz, Lodz, Poland.

Wosiak Agnieszka (W)

Laboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Medical University of Lodz, Lodz, Poland.

Pietrzak Jacek (P)

Laboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Medical University of Lodz, Lodz, Poland.

Agnieszka Jeleń (A)

Laboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Medical University of Lodz, Lodz, Poland. agnieszka.jelen@umed.lodz.pl.

Krygier Adrian (K)

Laboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Medical University of Lodz, Lodz, Poland.

Szmajda-Krygier Dagmara (SK)

Laboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Medical University of Lodz, Lodz, Poland.

Aleksandra Sałagacka-Kubiak (A)

Laboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Medical University of Lodz, Lodz, Poland.

Ewa Balcerczak (E)

Laboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Medical University of Lodz, Lodz, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH